ArticleInternational journal of nanomedicine2025
Precise Control of the in vivo Fate of Nanomicelles Efficiently Treats Advanced Rheumatoid Arthritis via EGFR/JNK/MMP9 Pathway.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Injectable Hyaluronic Acid-Functionalized Nanocomposite Hydrogel for Targeted Rheumatoid Arthritis Therapy via Concurrent ROS Attenuation and Macrophage Repolarization.International journal of nanomedicine · 2026Article
- Restoring macrophage iron homeostasis by natural carrier-free nanoplatform for the therapy of rheumatoid arthritis syndromes.Materials today. Bio · 2025Article
- The Therapeutic Potential of Phytochemicals Unlocks New Avenues in the Management of Rheumatoid Arthritis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Förster resonance energy transfer (FRET) technology is a tool for in vivo nanomedicine tracking. Nanomicelle-based drug carriers could improve therapeutic outcome for rheumatoid arthritis (RA). Self-assembled nanomicelles are a major type of them, and their drug-loading stability is seriously affected by the in vivo environment. Therefore, it is critical to understand the status of nanomicelles in vivo at different time points, in order to enable precise control of their dynamics to effectively deliver the drug to inflammatory joint. Methods: We applied FRET technology to elucidate the biofate of nanomicelles in an adjuvant induced arthritis (AIA) mice model and inflammatory larvae zebrafish models. We explored the molecular mechanism of swertiamarin-loaded nanomicelles (SWE-NMs) in improving RA symptoms through network pharmacology, molecular docking and immunofluorescence experiments. Results: Results showed that on cellular level the nanomicelles could enter inflammatory cells and completely release most cargoes in 12 h, while in animals, the majority of nanomicelles was destroyed within 72 h. Hence, we tailored an administration scheme for RA treatment. As expected, we loaded swertiamarin into the nanomicelles (SWE-NMs). The injection every 3 days (SWE-NMs/3) displayed enhanced accumulation in arthritic joints and strong anti-RA therapeutic effect, as well as good safety profile. In addition, network pharmacology, molecular docking analysis and immunofluorescence experiments revealed that SWE-NMs might work by blocking the epidermal growth factor receptor/c-Jun N-terminal kinase/matrix metalloproteinase (EGFR/JNK/MMP9) pathway. Conclusion: In summary, this study elucidated the biofate of nanomicelles with FRET technology in RA treatment, thus providing a basis for rationally improving administration scheme and giving clue for investigating other nano delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.